1.
J Neuroimmunol
; 359: 577690, 2021 10 15.
Article
in English
| MEDLINE | ID: covidwho-1347720
ABSTRACT
Case report describing a patient infected with COVID-19 after initiation of Cladribine, with a favorable disease course and positive seroconversion.
Subject(s)
COVID-19/immunology , Cladribine/therapeutic use , Immunity, Humoral/drug effects , Immunosuppressive Agents/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/immunology , COVID-19/diagnostic imaging , Cladribine/pharmacology , Drug Administration Schedule , Humans , Immunity, Humoral/physiology , Immunosuppressive Agents/pharmacology , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging , Treatment Outcome
2.
Mult Scler Relat Disord
; 46: 102476, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-733681
ABSTRACT
Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.
Subject(s)
Antibodies, Viral/immunology , Antibody Formation/immunology , COVID-19 Drug Treatment , Cladribine/pharmacology , SARS-CoV-2/drug effects , COVID-19/immunology , Female , Humans , Immunosuppressive Agents/pharmacology , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Multiple Sclerosis/virology , SARS-CoV-2/pathogenicity
3.
Mult Scler Relat Disord
; 46: 102469, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-731875